Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613350 | 0.88 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29728458 | 0.87 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL411680 | 0.87 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL31173373 | 0.87 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL3699996 | 0.85 | KMT2A (0.64) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL3757636 | 0.84 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL7113144 | 0.84 | KMT2A (0.75) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL3050635 | 0.84 | KMT2A (0.63) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL21332462 | 0.83 | KMT2A (0.66) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL20126921 | 0.83 | KMT2A (0.60) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021113698-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020227588-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | US | disclosed |
| US-20170266302-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | R.P. SCHERER TECHNOLOGIES, LLC | 2017-09-21 | — | — | US | disclosed |
| CN-103539797-B | Compounds of reverse turn mimetics and uses thereof | JW PHARMACEUTICAL CORPORATION (KR) | 2016-05-18 | — | — | CN | disclosed |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2015-02-26 | — | — | US | disclosed |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2015-02-26 | — | — | US | disclosed |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2015-02-26 | — | — | US | disclosed |
| US-8729262-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729262-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2014-05-20 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021431-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20060084655-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2006-04-20 | — | — | US | disclosed |
| US-20050059628-A1 | Modulation of beta-catenin/TCF-activated transcription | CHOONGWAE PHARMA CORPORATION (KR) | 2005-03-17 | — | — | US | disclosed |
| US-20040072831-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084655-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | KMT2A 4111/4885EPHX2 3707/4885CASP3 2025/4885 |
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | KMT2A 4111/4885EPHX2 3707/4885CASP3 2025/4885 |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | KMT2A 4111/4885EPHX2 3707/4885CASP3 2025/4885 |
| US-20070021431-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | KMT2A 4111/4885EPHX2 3707/4885CASP3 2025/4885 |
| US-20170266302-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | HNMT, TIAL1, HACL2 | KMT2A 515/4885EPHX2 300/4885CASP3 1957/4885 |
| US-20050059628-A1 | Modulation of beta-catenin/TCF-activated transcription | TCF4, TCF7, TCF7L2 | KMT2A 1550/4885EPHX2 3177/4885CASP3 1760/4885 |
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | DNPEP, PEPD, ANPEP | KMT2A 4615/4885EPHX2 2333/4885CASP3 1914/4885 |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | KMT2A 4111/4885EPHX2 3707/4885CASP3 2025/4885 |
| US-20040072831-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | KMT2A 4102/4885EPHX2 3697/4885CASP3 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.